Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease
RecruitingNCT07036328Phase: NAStarted 2025-04-07
Summary
New amyloid-targeting drugs for Alzheimer's disease (AD) offer minimal or unclear efficacy and often cause adverse events, highlighting the need for new therapies. In recent years, repetitive transcra
Eligibility
Sex
ALL
Min Age
50 Years
Max Age
85 Years
Locations
Amsterdam UMCAmsterdam, Netherlands
View full study details on ClinicalTrials.gov
clinicaltrials.gov/study/NCT07036328